The study identifies TRPM5 in CD4 T cells as a modulator of T cell activation and intestinal inflammation in a mouse colitis model, which could help researchers exploring new immune-pathway targets for IBD.

The paper suggests that HRQoL and family functioning may be similar across disease types and common treatment approaches in children with IBD, but emotional health and parental worry remain areas needing attention.

Depressive symptoms are common in IBD and can worsen quality of life and disease management; non-drug options that may improve mood are especially relevant for patients seeking adjunctive or accessible therapies.

Cure8 could only read part of this source from newsbytesapp.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease.

This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...

This DailyMed entry is an official FDA drug-label record describing indications, dosing, and safety information for sulfasalazine—an older prescription medication still used in ulcerative colitis. Updated label details...

Cure8 found this source from aero-news.net, but the page could not be read reliably yet. It is tagged for Community and awareness. Open the original article for the full details.

If confirmed, αvβ6 autoantibodies could help identify people at higher risk for ulcerative colitis and point to a new mechanism (blockade of epithelial TGF‑β activation) that contributes to mucosal inflammation.

The study presents a new oral NRF2 activator that reduced inflammation and tissue injury in a mouse model of ulcerative colitis, suggesting a potential novel therapeutic approach.

This study suggests that boosting Nrf2 activity in CD4+ T cells can reduce inflammatory Th1/Th17 responses and increase regulatory T cells, which may help control colonic inflammation in ulcerative colitis.

The study identifies a new molecular mechanism (CTSH citrullination) that appears to drive NETs formation and worsen colitis in mice, which could point toward future therapies targeting PAD4–CTSH–NETs pathways. That...

The study suggests chronic gut inflammation can cause measurable brain inflammation and neuronal dysfunction in an IBD model, and that creatine supplementation prevented those changes — a potential neuromodulatory...

This research suggests a common environmental contaminant (6PPD-quinone from tire rubber) can disrupt lipid metabolism and mitochondrial function in human colon cells and increase inflammatory signals linked to IBD.

People with IBD may be interested because the review identifies polysaccharides from traditional Chinese medicine as a potential source of new therapies that act on gut microbes, the intestinal barrier, and immune...

If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute...

Cure8 could only read part of this source from Перспективи та інновації науки, so this card uses cautious topic tags instead of a full summary. It is tagged for Complications.

Cure8 could only read part of this source from Перспективи та інновації науки, so this card uses cautious topic tags instead of a full summary. It is tagged for Microbiome and Research and clinical trials.

Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...

The study points to a new local mechanism—ferroportin in colon macrophages—that links iron handling, the microbiome, and mucosal healing. If validated, this could lead to targeted treatments that help healing without...

The paper identifies Siglec‑E as an immune brake that limits colitis severity and colitis‑associated tumor development in mice, connecting an immune‑regulatory pathway to inflammation‑driven colorectal cancer risk—an...

The paper identifies a biologic pathway that links epithelial AhR signaling to NK cell–mediated tumor surveillance in the colon. For people with IBD, mechanisms that increase immune escape could relate to...

A humanized DSS colitis model that recreates human T cell and myeloid responses could make preclinical testing of human-specific biologics (like anti-TNF antibodies) more relevant to people with IBD.

The study suggests C. difficile colonization may expand IL1B+ monocytes that recruit neutrophils and amplify inflammation in ulcerative colitis, a pathway that could help explain pathogen-associated flares.

If successful, orally available small-molecule α4β7 inhibitors could offer a non-injectable alternative to current antibody therapy (vedolizumab) that targets the same gut-homing integrin—potentially widening treatment...

Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...

This large US claims study compares safety outcomes (serious infections, heart attacks/stroke, and venous clots) for tofacitinib versus multiple biologic therapies in people with ulcerative colitis — questions many...

Cure8 found this source from Inflammatory bowel diseases, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original...

The work suggests soluble factors present in fecal filtrates from active UC patients can provoke proinflammatory responses in a controlled intestine-on-chip model, supporting the idea that microbiome-derived metabolites...

Based on the title and source metadata, this appears to be a regulatory update related to Colorectal cancer, Blood Test, and Tests and monitoring. The original article is from hmpgloballearningnetwork.com.

An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of...

This label update details how injectable methylprednisolone can be used in acute/critical situations for inflammatory bowel diseases (regional enteritis/Crohn’s disease and ulcerative colitis), including dosing and...

For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry...

Decisions about having children are common and sometimes complex for women living with IBD. This study maps different motivation patterns and the factors linked to them, which could help clinicians tailor reproductive...

RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.

Children with autoimmune gastrointestinal diseases can have impaired bone health.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from The American Journal of...

Sleep disturbance is common in IBD and may relate to disease risk and flares. Understanding which sleep problems are linked to onset or activity could point to new ways to support people with IBD.

Low-FODMAP diets are commonly used to reduce GI symptoms in IBS and sometimes in UC.

The study identifies a probiotic species (B. pseudolongum) and its acetate production as potential ways to limit a genotoxic E. coli and reduce inflammation in a mouse model — suggesting a microbiome-based avenue that...

If validated, epithelial CXCL1 could become a tissue biomarker that helps track remission specifically in ulcerative colitis and serve as a functional readout for epithelial-directed therapies tested in patient-derived...

A planned 5-year cohort focused on newly diagnosed Crohn’s patients could identify patterns of bowel damage and predictors of surgery or disability, which may eventually help tailor treatments and monitoring.

Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...

Early, noninvasive stool tests (fecal calprotectin and FIT) might identify whether vedolizumab or infliximab is likely to work within weeks instead of months. That could let patients and clinicians make treatment...

A new Phase 2 study is testing an investigational injectable drug (called “627”) for moderate to severe ulcerative colitis. People with UC who have not responded to or cannot tolerate current therapies are the intended...

Cure8 found this source from Alimentary pharmacology & therapeutics, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Tests and monitoring. Open the original article for the...

Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...

Early company-reported clinical responses in special-access patients and planned Phase 2 trials could signal a new stem-cell therapy approach advancing for fistulising Crohn’s disease — a complication that can be hard to...

Extra‑intestinal Crohn’s disease can first appear as chronic vulvar swelling and pain, which may be misdiagnosed in adolescents and young adults.